The highest-dose group in a phase 2 trial of eloralintide plus tirzepatide reached mean weight loss of 23.3% at 48 weeks, Endocrinology Advisor reports from ObesityWeek 2026 on 15 November. Tirzepatide 15 mg alone reached 14.8% in the same trial, and placebo reached 3.0%.
The combination is described as investigational, so these are trial results, not a prescribing decision. Take the numbers to your prescriber and ask what they could mean for your diabetes care and your weight.
What are the quick facts as of 2026-11-16?
The study is registered on ClinicalTrials.gov study record, a government registry run by the National Library of Medicine. Its details below come from that record, from Endocrinology Advisor, and from Eli Lilly's company release.
| Item | Details |
|---|---|
| Drug combination | Eloralintide plus tirzepatide. Lilly calls it EloraTZP. |
| Study phase | Phase 2 |
| Who was studied | Adults with overweight or obesity and type 2 diabetes |
| Length | 48 weeks |
| Enrollment | 367 participants (ClinicalTrials.gov, actual) |
| Sponsor | Eli Lilly and Company |
| Status | Completed (ClinicalTrials.gov); described as investigational |
| Where results were presented | ObesityWeek 2026, Washington, DC, 15 November 2026 (Endocrinology Advisor); EASD 2026, Milan, 30 September 2026 (Lilly release) |
| Top result | 23.3% mean weight loss, eloralintide 9 mg plus tirzepatide 15 mg (efficacy estimand) |
| Registry results | No results posted on ClinicalTrials.gov |
What was presented at ObesityWeek 2026?
Endocrinology Advisor reports that the study was presented as an oral session at ObesityWeek 2026 in Washington, DC, on 15 November 2026. Its reference names the presentation “Eloralintide phase 2 clinical outcomes,” by Almandoz J, Fruhbeck G, Hsia S, Billings L and Jastreboff A. The Endocrinology Advisor report calls the combination investigational and uses the name EloraTZP.
Eli Lilly's Eli Lilly's 30 September release is a company statement about its own study. It says the results were presented at EASD 2026 in Milan on 30 September 2026. Its numbers match the Endocrinology Advisor report, so you're reading the same results either way.
The trial was randomized, double-blind and placebo-controlled. The registry lists 367 enrolled participants and a 48-week primary outcome: percent change in body weight at week 48. Lilly's release says each drug was given as a separate injection.
How much weight did each group lose?
The table lists mean weight change at 48 weeks, using the efficacy estimand that both sources report. Rows marked Endocrinology Advisor come from that report. The other rows come from Lilly's release. Average starting weight was 105.4 kg (232.4 lbs).
| Arm | Mean weight change at 48 weeks | Source |
|---|---|---|
| Placebo | -3.0% | Endocrinology Advisor |
| Eloralintide 3 mg alone | -8.2% | Lilly release |
| Eloralintide 9 mg alone | -11.1% | Lilly release |
| Eloralintide 6 mg alone | -12.3% | Lilly release |
| Eloralintide 3 mg plus tirzepatide 5 mg | -13.2% | Lilly release |
| Tirzepatide 15 mg alone | -14.8% | Endocrinology Advisor |
| Eloralintide 6 mg plus tirzepatide 5 mg | -19.4% | Lilly release |
| Eloralintide 6 mg plus tirzepatide 10 mg | -19.9% | Endocrinology Advisor |
| Eloralintide 9 mg plus tirzepatide 15 mg | -23.3% (about 24.6 kg) | Endocrinology Advisor |
Endocrinology Advisor also describes a sequential arm, in which eloralintide 3 or 6 mg was added to tirzepatide 15 mg at week 24. The report also prints one figure above 100%. It is an evident typo, so this page leaves it out.
Read 23.3% as the result for one dose group, the highest one tested. Figures marked “up to” describe the top end of the range across groups.
What else did the trial measure?
For blood sugar, Lilly's release gives a baseline HbA1c of 8.1%. The top combination lowered HbA1c by 2.9 percentage points. Tirzepatide alone lowered it by 2.4, eloralintide alone by 1.1 to 1.4, and placebo by 0.3. Endocrinology Advisor reports HbA1c under 5.7% in up to 77% of participants.
Endocrinology Advisor reports waist reductions of up to 18.2 cm in the top combination, 11.6 cm with tirzepatide alone and 3.7 cm with placebo. For body mass index, up to 60% of the top combination group reached a BMI under 30, and 46% reached 25 or lower. With tirzepatide alone, those figures were 47% and 25%.
Ania Jastreboff, MD, PhD, a Yale study co-author, told Endocrinology Advisor the weight loss was of a “magnitude of which we haven't seen in previous studies in T2D.” She called the findings “very promising and exciting for our patients with T2D.” Lilly says all combinations met the primary and secondary endpoints.
What is eloralintide?
Eloralintide is the investigational drug in this combination. The registry identifies it as LY3841136. In this study it was given alone at three doses and combined with tirzepatide in five dose pairings. Tirzepatide served as the active comparison, given alone at 15 mg.
Lilly's release says it plans Phase 3 studies of an EloraTZP co-formulation by the end of 2026. For how eloralintide works and how it compares with your current diabetes medicines, ask your prescriber or a pharmacist.
Who was in the trial, and who might it affect?
MedlinePlus type 2 diabetes overview describes type 2 diabetes as a lifelong disease with a high level of sugar in the blood. The registry lists these eligibility rules for the trial:
- Ages 18 to 75
- BMI 27 or higher
- Type 2 diabetes with HbA1c between 7.0% and 10.5%
- HbA1c measured on diet and exercise, or on stable metformin with or without an SGLT2 inhibitor
Participants were randomized in the US and Argentina, according to Lilly's release. Baseline average waist was 118.2 cm, per Endocrinology Advisor. If your numbers sit near these ranges, bring these results to your prescriber.
Is eloralintide plus tirzepatide approved?
It is described as investigational. Both the Endocrinology Advisor report and Lilly's release use that word. Lilly plans Phase 3 studies next, as noted above, and your prescriber is the person to ask about where it stands for you.
What side effects were reported?
Lilly's release says the most common side effects were gastrointestinal, generally mild or moderate, mainly during dose escalation, and more frequent in the combination arms than with either drug alone. Lilly is speaking about its own trial here. Stopping treatment because of side effects looked like this:
| Group | Stopped treatment due to side effects (Lilly release) |
|---|---|
| Eloralintide plus tirzepatide combinations | 10.8% to 27.0% |
| Eloralintide alone | 0% to 10.8% |
| Tirzepatide | 2.9% |
| Placebo | 16.7% |
The Lilly release does not show serious adverse event counts. Ask your prescriber about serious side effects first, and how they would watch for them at each dose step.
What dates matter?
| Date | What happened |
|---|---|
| 20 September 2024 | Trial start (ClinicalTrials.gov, actual) |
| 1 July 2026 | Primary completion (ClinicalTrials.gov, actual) |
| 14 September 2026 | Study completion (ClinicalTrials.gov, actual) |
| 30 September 2026 | Lilly's release reports results presented at EASD 2026 in Milan |
| 15 November 2026 | ObesityWeek 2026 oral session in Washington, DC (Endocrinology Advisor) |
| 16 November 2026 | Endocrinology Advisor report published |
| End of 2026 | Lilly plans Phase 3 studies of an EloraTZP co-formulation |
What are the common mix-ups?
CagriSema is a different combination. The Medical Xpress report on CagriSema, dated 16 November 2026, covers cagrilintide plus semaglutide. That 68-week trial enrolled adults without diabetes and describes CagriSema as investigational. Keep its numbers separate from the eloralintide results.
The top number is one dose group. 23.3% belongs to eloralintide 9 mg plus tirzepatide 15 mg. It is not the average for every arm.
The figures come from a presentation and a company statement. ClinicalTrials.gov lists no posted results for this study. The numbers above come from the conference report and Lilly's release.
The two dates are one set of results. EASD on 30 September and ObesityWeek on 15 November both appear in the sources, with matching numbers.
What should you ask your prescriber?
- Are any studies of eloralintide, or of this combination, open to me?
- How would a combination like this fit with my current diabetes medicines?
- Given the stomach-related side effects in the trial, which ones would you watch for in me, and when?
- What would we do if side effects came up during a dose increase?
- Can you point me to the full published paper once it's out, so I can check the figures?
For more on weight and blood sugar, read our weight loss, blood sugar and digestion guide. For tirzepatide trial results beside semaglutide, see our semaglutide and tirzepatide clinical trials page.
By SterlingMedicalCenter.org Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
Read next